GS GSK GSK plc Loading... : Bullish and Bearish Analyst Opinions

Seeking Alpha highlights Stephen Ayers' bearish view that Moderna's mRESVIA is struggling against entrenched rivals Pfizer and GSK, with waning efficacy and a limited market dimming its blockbuster potential.

Short GSK because the high level of competition in the pharmaceutical industry makes it statistically improbable for GSK to exclusively develop a cure for asthma, negating a potential source of future upside.

Reeves explicitly states they have "secured a deal around pharmaceuticals" with the US which is "crucial for the UK" and asserts these terms are "not affected by the Supreme Court ruling" or current diplomatic tensions. While the broader UK-US trade relationship faces headwinds due to the UK's refusal to join offensive military action against Iran, the pharmaceutical sector has been ring-fenced. This regulatory certainty provides a safe harbor for UK pharma giants compared to other export sectors that may face retaliatory tariffs or "uncertainty." Long UK Pharma majors as a defensive play against geopolitical volatility; they retain access to their most critical market (US) regardless of the political spat. Unexpected executive orders from the US administration specifically targeting UK imports despite prior agreements.